Clinical Trial Update: A Study of UBT251 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH) [Phase 2]

View source ↗

Summary

UBT251 is being studied in Phase 2 for metabolic dysfunction-associated steatohepatitis (MASH). The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Metabolic Dysfunction-associated Steatohepatitis

Drugs mentioned

• UBT251

Snippet

Sponsor: The United Bio-Technology (Hengqin) Co., Ltd. | Conditions: Metabolic Dysfunction-associated Steatohepatitis (MASH) | Phase 2 | Status: RECRUITING